moxifloxacin has been researched along with urea in 8 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (urea) | Trials (urea) | Recent Studies (post-2010) (urea) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 45,450 | 2,047 | 9,188 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Braman, S; Capitano, B; Mattoes, HM; Nicolau, DP; O'Brien, A; Shore, E; Sutherland, C | 1 |
| Amitrano, M; Grossi, L; Manzoli, L; Marzio, L; Sacco, F; Spezzaferro, M | 1 |
| Berning, M; Jebens, C; Knoth, H; Krasz, S; Kuhlisch, E; Laass, MW; Lehn, N; Madisch, A; Miehlke, S; Morgner, A; Neumeyer, M; Schneider-Brachert, W; Stolte, M; Vieth, M; Zekorn, C | 1 |
| Brillault, J; Couet, W; Gobin, P; Gontijo, AV; Grégoire, N; Lamarche, I; Marchand, S | 1 |
| Cho, Y; Chung, KH; Hwang, JH; Jeong, SH; Jin, E; Kim, JW; Kim, N; Lee, DH; Seo, JY; Shin, CM | 1 |
| Almela, P; Angueira, T; Ariño, I; Barrio, J; Bermejo, F; Domínguez, JL; Domínguez-Muñoz, JE; Federico, A; Fernández, N; Fernandez-Bermejo, M; Ferrer-Barcelo, L; Gisbert, JP; Gomez, B; Gomez-Camarero, J; Gravina, AG; Lucendo, AJ; Marín, AC; Martin-Noguerol, E; Martorano, M; McNicholl, AG; Medina, E; Millastre, J; Miranda, A; Modolell, I; Molina-Infante, J; Ortuño, J; Perez-Aisa, Á; Perona, M; Rodríguez-Tellez, M; Romano, M | 1 |
| Abbasi, S; Brooks, A; Darpo, B; Dutta, S; Flach, S; Hsu, CP; Israel, S; Jafarinasabian, P; Lee, E; Terminello, B; Trivedi, A; Xue, H; Zhang, H | 1 |
4 trial(s) available for moxifloxacin and urea
| Article | Year |
|---|---|
Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults.
Topics: Aged; Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Azithromycin; Bronchoalveolar Lavage Fluid; Extravascular Lung Water; Female; Fluoroquinolones; Humans; Levofloxacin; Lung; Macrophages, Alveolar; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Urea | 2004 |
Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aza Compounds; Breath Tests; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Moxifloxacin; Quinolines; Urea; Young Adult | 2010 |
Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aza Compounds; Breath Tests; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Quinolines; Salvage Therapy; Time Factors; Treatment Outcome; Urea; White People | 2011 |
Omecamtiv mecarbil does not prolong QTc intervals at therapeutic concentrations.
Topics: Cross-Over Studies; Double-Blind Method; Electrocardiography; Fluoroquinolones; Heart Rate; Humans; Moxifloxacin; Urea | 2022 |
4 other study(ies) available for moxifloxacin and urea
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. Ciprofloxacin, moxifloxacin, and grepafloxacin.
Topics: Administration, Inhalation; Aerosols; Animals; Anti-Bacterial Agents; Biopharmaceutics; Bronchoalveolar Lavage Fluid; Cell Line; Ciprofloxacin; Fluoroquinolones; Humans; Macrophages, Alveolar; Male; Moxifloxacin; Piperazines; Rats; Rats, Sprague-Dawley; Urea | 2014 |
The efficacy of moxifloxacin-containing triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Cohort Studies; Drug Therapy, Combination; Female; Fluoroquinolones; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Organometallic Compounds; Peptic Ulcer; Rabeprazole; Republic of Korea; Retrospective Studies; Salvage Therapy; Stomach; Tetracycline; Treatment Failure; Treatment Outcome; Urea | 2014 |
Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Cohort Studies; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Moxifloxacin; Prospective Studies; Proton Pump Inhibitors; Retreatment; Treatment Failure; Treatment Outcome; Urea | 2015 |